Dr. Shosh Merchav has been involved in the field of Regenerative Medicine since the early 80's, both in the Academic as well as Industrial setting. Dr Merchav joined Teva in 2006 and has headed the Cell Therapy Projects Unit at Teva Innovative Ventures, where she was responsible for supporting and overseeing preclinical -to registration phase projects utilizing hematopoietic, adult,

mesenchymal and embryonic stem cells, in the fields of oncology, heart failure, neurodegenerative and peripheral artery disease. Prior to joining Teva Dr. Merchav served as Director of Research and Operations at ViaCell Singapore Pte. Ltd., which she established in 2002 as a subsidiary of ViaCell Inc., and managed till 2006.

Before joining the Biotech Industry Dr. Merchav held a tenured academic position from1986 till 2006 at the department of Cell Biology, Rappaport Faculty of Medicine, Technion, Israel, where she established and headed the Experimental Hematopoiesis and Cell Therapy Unit.

Dr. Merchav's translational research activities focused on normal and malignant hematopoiesis, identification and functional characterization of mesenchymal stem cells and Cord Blood Stem Cell Expansion technologies, the latter recently licensed to Pluristem Inc.

Dr Merchav has been an invited speaker and panelists in prestigious regenerative medicine conferences and workshops and currently serves as Board member in two Israeli cell therapy companies, MGVS and Cell Cure. She also initiated and chairs the Israel Cell Therapy Company Society, which constitutes of clinical-stage companies for knowledge sharing generic purposes of generic product development and regulatory issues.
Dr Merchav has also been serving as a panel evaluator for the European Commission Health Programmes specializing in stem cells, regenerative medicine and cell-based immune vaccines.   
Dr. Merchav holds a Ph.D. from Erasmus University, Rotterdam NL and an MBA degree from Haifa University Business School.